The said contracts have been awarded to Duopharma (M) Sendirian Berhad, a wholly-owned subsidiary of Duopharma Biotech.

As part of these contracts, Biocon’s subsidiary, Biocon Sdn. Bhd., Malaysia, will supply short-acting recombinant human insulin, insulin glargine and insulin aspart to Duopharma (M) Sendirian Berhad for distribution.

The contracts comprise a three-year agreement valued at MYR 155.27 million for human insulin, along with two two-year agreements, which consists of MYR 18 million contract for insulin glargine and MYR 52.5 million contract for insulin aspart.

Shreehas Tambe, CEO & managing director, Biocon, said: “Malaysia has been central to Biocon’s insulin journey for over a decade, anchored by our integrated insulin manufacturing facility in the country – the largest in Asia.

Our Johor operations enable us to deliver insulin at scale, expanding patient access in Malaysia and around the world.”

Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.

The company had reported 63.4% drop in consolidated net profit to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations rose by 2.26% year-on-year (YoY) to Rs 4,517 crore during the period under review.

The scrip shed 0.17% to currently trade at Rs 422.65 on the BSE.